PDL BIOPHARMA INC's ticker is and the CUSIP is 69329YAG9. A total of 10 filers reported holding PDL BIOPHARMA INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 2.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $54,000 | 0.0% | 53,000 | 0.0% | 0.10% | -9.2% |
| Q2 2021 | $54,000 | -99.5% | 53,000 | -99.5% | 0.11% | -99.5% |
| Q2 2020 | $10,272,000 | +0.1% | 9,702,000 | -0.6% | 20.58% | -5.6% |
| Q1 2020 | $10,257,000 | -3.6% | 9,762,000 | -1.4% | 21.80% | +3.4% |
| Q4 2019 | $10,640,000 | +11.4% | 9,901,000 | -0.4% | 21.09% | +0.6% |
| Q3 2019 | $9,552,000 | -9.8% | 9,937,000 | -1.5% | 20.97% | -18.8% |
| Q2 2019 | $10,594,000 | -9.9% | 10,092,000 | -1.8% | 25.84% | +13.5% |
| Q1 2019 | $11,755,000 | -7.6% | 10,278,000 | -18.2% | 22.76% | -11.8% |
| Q4 2018 | $12,721,000 | +0.7% | 12,562,000 | -1.9% | 25.80% | +19.1% |
| Q3 2018 | $12,636,000 | +5.9% | 12,804,000 | -1.5% | 21.66% | +12.0% |
| Q2 2018 | $11,937,000 | -13.4% | 13,002,000 | -4.0% | 19.35% | -9.0% |
| Q1 2018 | $13,781,000 | +6.2% | 13,538,000 | +0.4% | 21.27% | -2.5% |
| Q4 2017 | $12,973,000 | – | 13,487,000 | – | 21.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SMH CAPITAL ADVISORS INC | 12,804,000 | $12,636,000 | 21.66% |
| Context Partners Fund, L.P. | 7,175,000 | $7,034,000 | 4.09% |
| Context Capital Management, LLC | 7,175,000 | $7,034,000 | 4.09% |
| Pinnacle Holdings, LLC | 3,260,000 | $3,217,213,000 | 1.11% |
| Venator Capital Management Ltd. | 2,000,000 | $1,960,000 | 0.98% |
| LINDEN ADVISORS LP | 26,617,000 | $26,292,000 | 0.80% |
| WHITEBOX ADVISORS LLC | 21,681,000 | $21,396,000 | 0.65% |
| WOLVERINE ASSET MANAGEMENT LLC | 16,852,000 | $16,518,000 | 0.19% |
| OAKTREE CAPITAL MANAGEMENT LP | 4,695,000 | $4,657,000 | 0.06% |
| AQR Arbitrage LLC | 3,150,000 | $3,124,000 | 0.04% |